Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Research & Development (2022 - 2026)

Zentalis Pharmaceuticals has reported Research & Development over the past 5 years, most recently at $28.7 million for Q1 2026.

  • For Q1 2026, Research & Development rose 5.39% year-over-year to $28.7 million; the TTM value through Mar 2026 reached $108.8 million, down 25.21%, while the annual FY2025 figure was $107.3 million, 36.05% down from the prior year.
  • Research & Development for Q1 2026 was $28.7 million at Zentalis Pharmaceuticals, down from $29.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $51.6 million in Q4 2023 and troughed at $23.0 million in Q3 2025.
  • A 5-year average of $39.2 million and a median of $42.2 million in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: increased 26.94% in 2023 and later crashed 45.05% in 2025.
  • Year by year, Research & Development stood at $40.6 million in 2022, then increased by 26.94% to $51.6 million in 2023, then crashed by 36.05% to $33.0 million in 2024, then fell by 10.57% to $29.5 million in 2025, then dropped by 2.62% to $28.7 million in 2026.
  • Business Quant data shows Research & Development for ZNTL at $28.7 million in Q1 2026, $29.5 million in Q4 2025, and $23.0 million in Q3 2025.